TAP Licenses Investigational PPI As Part Of Gastroenterological Focus
This article was originally published in The Pink Sheet Daily
Executive Summary
New investigational proton pump inhibitor, licensed from Seoul, Korea-based Ilyang, will enter Phase II trials in 2006, TAP reports.